08:00 , Dec 8, 2003 |  BC Week In Review  |  Company News

Atrix, curasan AG sales and marketing update

curasan received exclusive marketing rights in Germany to Atridox and Atrisorb from ATRX. Atridox is a specific local antibiotic, and Atrisorb is a bioabsorbable membrane that is applied as a liquid. Atrix Laboratories Inc. (ATRX),...
08:00 , Feb 19, 2002 |  BC Week In Review  |  Company News

Atrix, CollaGenex sales and marketing update

CGPI launched in the U.S. ATRX's Atrisorb-D, a guided tissue regeneration barrier membrane with doxycycline, under the companies' 2001 marketing deal (see BioCentury, Sept. 4, 2001). Atrix Laboratories Inc. (ATRX), Fort Collins, Colo.   CollaGenex...
08:00 , Dec 17, 2001 |  BC Week In Review  |  Company News

Atrix, CollaGenex, PharmaScience Inc. sales and marketing update

PharmaScience will exclusively market in Canada ATRX's Atridox , Atrisorb Free-Flow and Atrisorb-D dental products. In addition, PharmaScience will distribute Periostat in Canada for ATRX's U.S. marketing partner, CGPI, upon marketing approval. Atrix Laboratories Inc....
07:00 , Sep 4, 2001 |  BC Week In Review  |  Company News

Atrix, CollaGenex, Block Drug Co. Inc. deal

ATRX reobtained rights from Block to its dental products, including its Atridox periodontal disease products, for $7 million, $3.3 million of which ATRX will pay upfront and the remainder of which will come from Atridox...
07:00 , Apr 30, 2001 |  BC Week In Review  |  Company News

Atrix, Block Drug Co. Inc. dental news

ATRX said the companies settled a pricing dispute regarding BLOCA's sale of ATRX's Atridox doxycycline antibiotic for periodontal disease. As settled, ATRX said it received a payment for product sales in 1999. ATRX said the...
07:00 , Apr 3, 2000 |  BC Week In Review  |  Company News

Atrix, Merck KGaA sales and marketing update

Merck subsidiary Genmedix Ltd. (Netanya, Israel) will exclusively distribute in Israel ATRX's Atrisorb and Atrisorb Direct guided tissue regeneration barriers for use during periodontal surgery. Genmedix also will assist ATRX in registering Atridox 8.8 percent...
08:00 , Feb 14, 2000 |  BC Week In Review  |  Clinical News

Atrisorb and FreeFlow regulatory update

ATRX submitted 510(k) applications to the FDA for its Atrisorb kit and FreeFlow guided tissue regeneration (GTR) barriers containing the antibiotic doxycycline to reduce microbial contamination during periodontal surgery. Block Drug Corp. (BLOCA, Jersey City,...
07:00 , Sep 14, 1998 |  BC Week In Review  |  Clinical News

Atrix regulatory update

ATRX received received FDA marketing approval for its Atridox doxycycline hyclate 10 percent site-specific antibiotic to treat periodontal disease. The company also received 510(k) clearance from the FDA for its Atrisorb FreeFlow GTR Barrier, which...
07:00 , Sep 14, 1998 |  BioCentury  |  Finance

Atrix Laboratories Inc. (ATRX)

Atrix Laboratories Inc. (ATRX) The weekly change in the indexed market value of Atrix Laboratories Inc. (ATRX, dotted line with triangles) compared to The Carson Life Sciences Index of 190 smaller cap companies (<$500M, solid...
07:00 , Jul 13, 1998 |  BC Week In Review  |  Clinical News

Atrisorb tissue regeneration barrier containing doxycycline: ATRX will begin a 120-patient pivotal trial

Atrix Laboratories Inc. (ATRX), Fort Collins, Colo.   Product: Atrisorb tissue regeneration barrier containing doxycycline   Indication: Treat periodontal disease   Status: ATRX will begin a 120-patient pivotal trial with its second-generation version of Atrisorb...